SAN DIEGO--(BUSINESS WIRE)--Jan. 30, 2006--AVANIR Pharmaceuticals (AMEX:AVN.R) announced today that on Friday, January 27, 2006, it completed the submission of its new drug application (NDA) to the U.S. Food and Drug Administration (FDA) for Neurodex(TM), seeking marketing approval of the drug candidate for the treatment of involuntary emotional expression disorder, also known as pseudobulbar affect or emotional lability. The application was resubmitted to the FDA to provide an expansion of certain summary analyses which better support the electronic common technical document (e-CTD) format.
